Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

BiDil: assessing a race-based pharmaceutical.

Howard Brody1, Linda M Hunt

  • 1Department of Family Practice and the Center for Ethics and Humanities in the Life Sciences, Michigan State University, East Lansing, MI, USA. habrody@utmb.edu

Annals of Family Medicine
|December 7, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Narrative Ethics, COVID-19, and Flawed Stories.

Perspectives in biology and medicine·2022
Same author

Are Corporations Re-Defining Illness and Health? The Diabetes Epidemic, Goal Numbers, and Blockbuster Drugs.

Journal of bioethical inquiry·2021
Same author

Corporate Logic in Clinical Care: The Case of Diabetes Management.

Medical anthropology quarterly·2019
Same author

Meaning and an Overview of the Placebo Effect.

Perspectives in biology and medicine·2018
Same author

Racialized Risk in Clinical Care: Clinician Vigilance and Patient Responsibility.

Medical anthropology·2018
Same author

Futility: Definition and Goals.

Perspectives in biology and medicine·2018
Same journal

Advancing Family Medicine Through Dyadic Electronic Medical Record Linkage in Dementia Care.

Annals of family medicine·2026
Same journal

Association of General Practice Continuity With Hospital Admissions and Costs: A Retrospective Study.

Annals of family medicine·2026
Same journal

Association of Advanced Access With Primary Care Performance: A Systematic Review.

Annals of family medicine·2026
Same journal

Death by Rousui in Japan: Rethinking Death, Diagnosis, and Care in an Aging Society.

Annals of family medicine·2026
Same journal

Multicomponent School of Caring Program to Support Caregivers of Patients With Dementia: A Quasi-Experimental Effectiveness Study in Primary Care.

Annals of family medicine·2026
Same journal

Addressing Primary Care Needs of Cancer Survivors: The Primary Care Engaged Research for Cancer Survivorship Care (PERCS) Initiative.

Annals of family medicine·2026
See all related articles

BiDil, a heart failure drug for African Americans, raises questions about race, efficacy in other groups, and healthcare disparities. Physicians should consider cost and availability for patients.

Area of Science:

  • Cardiology
  • Pharmacology
  • Health Equity

Background:

  • The fixed-dose combination of isosorbide and hydralazine (BiDil) was the first FDA-approved drug for a specific racial-ethnic group: African Americans with congestive heart failure.
  • The drug's approval was based solely on studies in African American populations, leaving its efficacy in other groups unknown.
  • The use of race as a biological construct in medicine is controversial, and BiDil highlights potential issues with overlooking sociocultural factors in disease causation.

Purpose of the Study:

  • To inform family physicians about the background issues surrounding BiDil's approval and marketing.
  • To discuss the implications of race as a medical construct and its role in BiDil's development.
  • To raise awareness of potential health disparities and socioeconomic factors related to BiDil's accessibility.

Related Experiment Videos

Main Methods:

  • Review of the scientific research and regulatory process leading to BiDil's approval.
  • Analysis of the implications of race-based drug approval in clinical practice.
  • Consideration of the commercial and ethical aspects of BiDil's marketing.

Main Results:

  • BiDil's efficacy in populations other than African Americans remains unproven.
  • The drug's approval process raises concerns about the oversimplification of race as a genetic determinant.
  • Past and present healthcare disparities for African American patients are critical considerations.

Conclusions:

  • BiDil's approval, while potentially benefiting an underserved group, sets a concerning precedent.
  • Physicians must be aware of the limitations of race-based medicine and potential generic alternatives.
  • Understanding the complexities of BiDil is crucial for equitable patient counseling and care.